The company's proprietary treatment is based on more than 10 years of research from Kingdom Hospital in Copenhagen Denmark, and has been shown to increase sperm production and function in preclinical and two clinical studies including a randomized clinical trial of infertile men. XY Therapeutics has identified and patented a biomarker that can select the men who will benefit from this treatment, and is currently developing it into a companion diagnostic that can allow clinicians and fertility experts to select the infertile men that will receive the treatment within minutes. The treatment is safe and only a single injection is required to observe the expected effect. Currently being tested in a Phase 2A trial, the expected positive result will provide a significant breakthrough in a field where there currently exists only very few available treatments for select subgroups of male infertility, with a broad impact on several aspects of citizens suffering from infertility from personal, societal, and economic perspectives.